First-trimester screening for pre-eclampsia: Moving from personalized risk prediction to prevention: Editorial

Ultrasound in Obstetrics and Gynecology

Volumn 45, Issue 2, 2015, Pages 119-129

  Baschat, A A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; PRE-ECLAMPSIA; PREGNANCY; RISK ASSESSMENT; RISK FACTOR;

FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK ASSESSMENT; RISK FACTORS;

EID: 84922602232     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.14770     Document Type: Editorial

References (128)

1. Chesley LC. History and epidemiology of preeclampsiaeclampsia. Clin Obstet Gynecol 1984; 27: 801-820.
2. Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO Chronicle Geneva: World Health Organization 1968; 22: 473.
3. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of pre-eclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
4. Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, Godines M, Parry S, Macones G, Strauss JF. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomized controlled trial. BMJ 2011; 342: d2901.
5. Ayala DE, Hermida RC. Ambulatory blood pressure monitoring for the early identification of hypertension in pregnancy. Chronobiol Int 2013; 30: 233-259.
6. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks model in early screening for pre-eclampsia. Fetal Diagn Ther 2012; 32: 171-178.
7. Easterling TR, Benedetti TJ, Schmucker BC, Millard SP. Maternal haemodynamics in normal and pre-eclamptic pregnancies: A longitudinal study. Obstet Gynecol 1990; 76: 1061-1069.
8. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.
9. Hinselmann H. In Die Eklampsie. Frederick Cohen: Bonn, 1924; 27-33.
10. White PW. Diabetes complicating pregnancy. Am J Obstet Gynecol 1938; 33: 380-385.
11. nd edn), Gustav-Fischer Jena 1923; 508-520.
12. Lehman K. Eklampsien i Danmark i aarene 1918-1927. Copenhagen: Busck, 1933.
13. Bublitschenko L. Zur Frage über gewisse konstitutionelle Eigentümlichkeiten bei Eklamptischen. Monatsschrift für Geburtshilfe und Gynäkologie 1925; 69: 139.
14. Davies AM. Geographic and ethnic differences in incidence of the pregnancy toxemias. Path Microbiol 1970; 35: 210-214.
15. Cuckle HS. Screening for pre-eclampsia - lessons from aneuploidy screening. Placenta 2011; 32: S42-48.
16. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 2010; 33: 1-22.
17. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
18. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Screening for pre-eclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203: 383.e1-8.
19. Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martinez A, Quezada S. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 2013; 41: 538-544.
20. Herraiz I, Arbués J, Camaño I, Gómez-Montes E, Grañeras A, Galindo A. Application of a first-trimester predictionmodel for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenat Diagn 2009; 29: 1123-1129.
21. Scazzocchio E, Figueras F, Crispi F, Meler E,MasollerN,Mula R, Gratacos E. Performance of a first-trimester screening of pre-eclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013; 208: 203.e1-10.
22. Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG. Prediction of preeclampsia utilizing the first trimester screening examination. Am J Obstet Gynecol 2014; 211: 514.e1-7.
23. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, Nelson DM. First-trimester placental protein 13, PAPP-A, uterine artery Doppler andmaternal characteristics in the prediction of pre-eclampsia. Placenta 2011; 32: 598-602.
24. Kuc S, Koster M, Franx A, Schielen PC, Visser GH. Maternal characteristics, mean arterial pressure and serum markers in early prediction of pre-eclampsia. PLoS One 2013; 8: e63546.
25. Caradeux J, Serra R, Nien J, Pérez-Sepulveda A, Schepeler M, Guerra F, Gutiérrez J, Martínez J, Cabrera C, Figueroa-Diesel H, Soothill P, Illanes S. First trimester prediction of early onset pre-eclampsia using demographic, clinical, and sonographic data: a cohort study. Prenat Diagn 2013; 33: 732-736.
26. Oliveira N, Magder LS, Blitzer MG, Baschat AA. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol 2014; 44: 279-285.
27. Baschat AA, Poon, LY, Blitzer M, Nicolaides K, Harman C. Impact of first-trimester aspirin on population prevalence of pre-eclampsia. Ultrasound Obstet Gynecol 2009; Suppl; OC08.05.
28. Block-Abraham DM, Turan OM, Doyle LE, Kopelman JN, Atlas RO, Jenkins CB, Blitzer MG, Baschat AA. First-trimester risk factors for pre-eclampsia development in women initiating aspirin by 16 weeks of gestation. Obstet Gynecol 2014; 123: 611-617.
29. Leslie K, Thilaganathan B, Papageorghiou A. Early prediction and prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25: 343-354.
30. Sibai B. First-trimester screening with combined maternal clinical factors, biophysical and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they ready for clinical use? BJOG 2014 doi: 10.1111/1471-0528.13052 [Epub ahead of print].
31. Kane SC, Da Silva Costa F, Brennecke SP. New directions in the prediction of pre-eclampsia. Aust N Z J Obstet Gynaecol 2014; 54: 101-107.
32. Farina A, Rapacchia G, Freni Sterrantino A, Pula G, Morano D, Rizzo N. Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia. Prenat Diagn 2011; 31: 1147-1152.
33. Oliveira N, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG, Baschat AA. External validity of first-trimester algorithms in the prediction of pre-eclampsia disease severity. Ultrasound Obstet Gynecol 2014; 44: 286-292.
34. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343: 619-629.
35. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-1798.
36. Bujold E, Roberge S, Nicolaides KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn 2014; 34: 642-648.
37. Martinez-Frias ML, Rodriguez-Pinilla E, Pietro L. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 1997; 56: 241-243.
38. Levefre ML. Low-dose aspirin use for the prevention of morbidity and mortality from pre-eclampsia: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2014; 161: 819-826.
39. Villa PM, Kajantie E, Räikkönen K, Pesonen AK, Hämäläinen E, Vainio M, Taipale P, Laivuori H; PREDO Study group. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomized placebo-controlled PREDO Trial and a meta-analysis of randomized trials. BJOG 2013; 120: 64-74.
40. Conde-Agudelo A, Romero R, Kusanovic JP, Hassan SS. Supplementation with vitamins C and E during pregnancy for the prevention of pre-eclampsia and other adverse maternal and perinatal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol 2011; 204: 503.e1-503.e12.
41. Patrelli TS, Dall'asta A, Gizzo S, Pedrazzi G, Piantelli G, Jasonni VM, Modena AB. Calcium supplementation and prevention of preeclampsia: a meta-analysis. J Matern Fetal Neonatal Med 2012; 25: 2570-2574.
42. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews, Issue 8, 2010. 10.1002/14651858.CD001059.pub3.
43. McCance DR, Holmes VA,Maresh MJ, Patterson CC, Walker JD, Pearson DW, Young IS, Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial. Lancet 2010; 376: 259-266.
44. Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J, De Greeff A, Poston L, Shennan A; WHO Vitamin C and Vitamin E trial group. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009; 116: 780-788.
45. Pijnenborg R, Bland JM, Robertson WB, Brosens I. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983; 4: 397-413.
46. Scholten RR, Hopman MT, Sweep FC, Van de Vlugt MJ, Van Dijk AP, Oyen WJ, Lotgering FK, Spaanderman ME. Co-occurrence of cardiovascular and prothrombotic risk factors in women with a history of pre-eclampsia. Obstet Gynecol 2013; 121: 97-105.
47. Rurangirwa AA, Gaillard R, Steegers EA, Hofman A, Jaddoe VW. Hemodynamic adaptations in different trimesters among nulliparous and multiparous pregnant women; the Generation R study. Am J Hypertens 2012; 25: 892-899.
48. Block-Abraham DM, Turan OM, Doyle LE, Kopelman JN, Atlas RO, Jenkins CB, Harman CR, Blitzer MG, Baschat AA. First trimester maternal characteristics, Doppler parameters and serum analytes after pre-eclampsia. Hypertens Pregnancy 2014; 33: 204-214.
49. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013; 28: 1-19.
50. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Pre-eclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800-809.
51. Ray JG, Schull MJ, Kingdom JC, Vermeulen MJ. Heart failure and dysrhythmias after maternal placental syndromes: HAD MPS Study. Heart 2012; 98: 1136-1141.
52. Svensson A, Andersch B, Hansson L. Prediction of later hypertension following a hypertensive pregnancy. J Hypertens Suppl 1983; 1: 94-96.
53. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005; 366: 1797-1803.
54. Smith GSC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001; 357: 2002-2006.
55. Di LorenzoG, Ceccarello M, Cecotti V, Ronfani L,Monasta L, Vecchi Brumatti L, Montico M, D'Ottavio G. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of pre-eclampsia. Placenta 2012; 33: 495-501.
56. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo AO. Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free β-hCG. Prenat Diagn 2010; 30: 1138-1142.
57. Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA; SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013; 120: 1215-1223.
58. D'Antonio F, Rijo C, Thilaganathan B, Akolekar R, Khalil A, Papageourgiou A, Bhide A. Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications. Prenat Diagn 2013; 33: 839-847.
59. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Thorp JMJr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Iams JD, Sciscione A, Harper M, Tolosa JE, SaadeG, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of pre-eclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119: 1234-1242.
60. Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6weeks in the prediction of late (>34 weeks) pre-eclampsia. Prenat Diagn 2011; 31: 1141-1146.
61. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011; 342: d1875.
62. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, Cuckle H, Wolf M. First-trimester placental protein 13 screening for pre-eclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197: 35e1-7.
63. Vandenberghe G, Mensink I, Twisk JW, Blankenstein MA, Heijboer AC, van Vugt JM. First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. Prenat Diagn 2011; 31: 955-961.
64. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, Gibor Y. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008; 115: 1465-1472.
65. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop pre-eclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-1038.
66. Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010; 30: 216-223.
67. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818.
68. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. Decreased PAPP-A is associated with pre-eclampsia, premature delivery and small for gestational age infants but not with placental abruption. Eur J Obstet Gynecol Reprod Biol 2011; 157: 48-52.
69. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
70. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38: 64-80.
71. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
72. Ray JG, Vermeulen MJ, Schull MJ, McDonald S, Redelmeier DA.Metabolic syndrome and the risk of placental dysfunction. J Obstet Gynaecol Can 2005; 27: 1095-1101.
73. Srinivas SK, Sammel MD, Bastek J, Ofori E, Andrela CM, Wolfe ML, Reilly M, Elovitz MA. Evaluating the association between all components of the metabolic syndrome and pre-eclampsia. J Matern Fetal Neonatal Med 2009; 22: 501-509.
74. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in pre-eclampsia. Metabolism 1999; 48: 892-896.
75. Villa PM, Laivuori H, Kajantie E, Kaaja R. Free fatty acid profiles in pre-eclampsia. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 17-21.
76. Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, White RR, Roddy M, Hladunewich M; Pre-Eclampsia New Emerging Team (PE-NET). A history of pre-eclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol 2009; 200: 58.e1-8.
77. Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA. Classic and novel risk factor parameters in women with a history of pre-eclampsia. Hypertension 2003; 42: 39-42.
78. Ramundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122: 579-584.
79. Stekkinger E, Scholten R, van der Vlugt MJ, van Dijk AP, Janssen MC, Spaanderman ME. Metabolic syndrome and the risk for recurrent pre-eclampsia: a retrospective cohort study. BJOG 2013; 120: 979-986.
80. Zheng J, Shan PF, Gu W. The efficacy of metformin in pregnant women with polycystic ovary syndrome: A meta-analysis of clinical trials. J Endocrinol Invest 2013: 36: 797-802.
81. Salvesen KA, Vanky E, Carlsen SM. Metformin treatment in pregnant women with polycystic ovary syndrome - is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet Gynecol 2007; 29: 433-437.
82. Zhuo Z, Wang A, Yu H. Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res 2014; 2014: 381231.
83. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor and social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19: 1323-1330.
84. Charlton F, Tooher J, Rye KA, Hennessy A. Cardiovascular risk, lipids and pregnancy: pre-eclampsia and the risk of later life cardiovascular disease. Heart Lung Circ 2014; 23: 203-212.
85. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, Novack L. Association of lipid levels during gestation with pre-eclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 2009; 201: 482.e1-8.
86. Sep S, Rijvers C, Smits L, van Bilsen M, Bekers O, Peeters L. Early-pregnancy changes in maternal lipid profile in women with recurrent pre-eclampsia and previously preeclamptic women with normal next pregnancy. Reprod Sci 2011; 18: 998-1004.
87. Baker AM, Klein RL, Moss KL, Haeri S, Boggess K. Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe pre-eclampsia. Am JObstet Gynecol 2009; 201: 293.e1-4.
88. Enquobahrie DA, Williams MA, Butler CL, Frederick IO, Miller RS, Luthy DA. Maternal plasma lipid concentrations in early pregnancy and risk of pre-eclampsia. Am J Hypertens 2004; 17: 574-581.
89. Ogura K, Miyatake T, Fukui O, Nakamura T, Kameda T, Yoshino G. Low-density lipoprotein particle diameter in normal pregnancy and pre-eclampsia. J Atheroscler Thromb 2002; 9: 42-47.
90. Bayhan G, Koc¸yigit Y, Atamer A, Atamer Y, Akkus Z. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in pre-eclampsia. Gynecol Endocrinol 2005; 21: 1-6.
91. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GD, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol 2013; 209: 373.e1-5.
92. Kusters DM, Hassani Lahsinoui H, van de Post JA, Wiegman A, Wijburg FA, Kastelein JJ, Hutten BA. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 2012; 10: 363-378.
93. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates pre-eclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108: 1451-1455.
94. Prevention of Adverse Pregnancy Outcome with Vitamin D Supplementation during Pregnancy. Clinicaltrials.gov: NCT01418664.
95. Pravastatin for the Prevention of Pre-eclampsia in High-Risk Women: A Phase I Pilot Study. Clinicaltrials.gov: NCT01717586.
96. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the JointNational Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
97. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
98. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 1990; 163: 1691-1712.
99. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-22.
100. Redman CW. Hypertension in pregnancy: The NICE guidelines. Heart 2011; 97: 1967-1969.
101. European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L; ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147-3197.
102. Bakker R, Steegers EA, Hofman A, Jaddoe VW. Blood pressure in different gestational trimesters, fetal growth, and the risk of adverse birth outcomes: the generation R study. Am J Epidemiol 2011; 174: 797-806.
103. McCowan LM, Thompson JM, Taylor RS, North RA, Poston L, Baker PN, Myers J, Roberts CT, Dekker GA, Simpson NA, Walker JJ, Kenny LC; SCOPE Consortium. Clinical prediction in early pregnancy of infants small for gestational age by customised birthweight centiles: findings from a healthy nulliparous cohort. PLoS One 2013; 8: e70917.
104. Steer PJ, Little MP, Kold-Jensen T, Chapple J, Elliott P. Maternal blood pressure in pregnancy, birth weight, and perinatal mortality in first births: prospective study. BMJ 2004; 329: 1312.
105. Grünberger W, Leodolter S, Parschalk O. Maternal hypotension: fetal outcome in treated and untreated cases. Gynecol Obstet Invest 1979; 10: 32-38.
106. Gaillard R, Bakker R, Willemsen SP, Hofman A, Steegers EA, Jaddoe VW. Blood pressure tracking during pregnancy and the risk of gestational hypertensive disorders: the Generation R Study. Eur Heart J 2011; 32: 3088-3097.
107. Bouthoorn SH, Gaillard R, Steegers EA, Hofman A, Jaddoe VW, van Lenthe FJ, Raat H. Ethnic differences in blood pressure and hypertensive complications during pregnancy: the Generation R study. Hypertension 2012; 60: 198-205.
108. Block-Abraham D, Turan OM, Doyle LE, Kopelman J, Atlas RO, Jenkins CB, Harman CR, Baschat AA. In the first trimester, a broad definition of hypertension is critical in defining pre-eclampsia risk. Am J Obstet Gynecol 2014; 210: S127.
109. Scantlebury DC, Schwartz GL, Acquah LA, White WM, Moser M, Garovic VD. The treatment of hypertension during pregnancy: when should blood pressure medications be started? Curr Cardiol Rep 2013; 15: 412.
110. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis. Lancet 2000; 355: 87-92.
111. Easterling TR, Brateng D, Schmucker B, Brown Z,Millard SP. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 1999; 93: 725-733.
112. Kertschanska S, Kosanke G, Kaufmann P. Pressure dependence of so-called transtrophoblastic channels during fetal perfusion of human placental villi. Microsc Res Tech 1997; 38: 52-62.
113. Burton GJ,Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009; 30: 473-482.
114. Ankumah NA, Cantu J, Jauk V, Biggio J, Hauth J, Andrews W, Tita AT. Risk of adverse pregnancy outcomes in women with mild chronic hypertension before 20 weeks of gestation. Obstet Gynecol 2014; 123: 966-972.
115. Dowell RT, Kauer CD. Maternal hemodynamics and uteroplacental blood flow throughout gestation in conscious rats. Methods Find Exp Clin Pharmacol 1997; 19: 613-625.
116. Reynolds LP, Borowicz PP, Caton JS, Vonnahme KA, Luther JS, Buchanan DS, Hafez SA, Grazul-Bilska AT, Redmer DA. Uteroplacental vascular development and placental function: an update. Int J Dev Biol 2010; 54: 355-366.
117. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine vs metoprolol in the treatment of hypertension during pregnancy: A randomized comparative trial. Obstet Gynecol 1994; 84: 354-359.
118. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication vs methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162: 960-966.
119. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007: CD002252.
120. Schramm AM, Clowse ME. Aspirin for prevention of pre-eclampsia in lupus pregnancy. Autoimmune Dis 2014; 2014: 920467
121. Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013; 7: CD006780.
122. de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014; 7: CD004734
123. The EPPI Trial - Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction - a pilot randomized open-label trial. ACTRN12609000699268.
124. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe pre-eclampsia. Am J Obstet Gynecol 2001; 185: 781-785.
125. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere pre-eclampsia. Am J Obstet Gynecol 2003; 189: 391-394.
126. Salehi-Pourmehr H, Mohamad-Alizadeh S, Malakouti J, Farshbaf-Khalili A. Association of the folic acid consumption and its serum levels with pre-eclampsia in pregnant women. Iran J Nurs Midwifery Res 2012; 17: 461-466.
127. Li Z, Ye R, Zhang L, Li H, Liu J, Ren A. Folic acid supplementation during early pregnancy and the risk of gestational hypertension and pre-eclampsia. Hypertension 2013; 61: 873-879.
128. Effect of Folic Acid Supplementation in Pregnancy on Pre-eclampsia-Folic Acid Clinical Trial (FACT). Clinicaltrials. gov: NCT01355159.